Abstract: A method for sample preparation for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response and suspected of having an infection. Also, a method for sample preparation for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response. The method comprises providing a sample from said patient and determining a level of PCT or fragment(s) thereof in said sample, wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required.

Abstract: A method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response and suspected of having an infection. Also, a method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response, wherein the comorbidity is preferably selected from the group comprising metabolic disorder (obesity), diabetes, hypertension, renal disease, thrombosis, malignancy or cancer, and suspected of having an infection. In particular, the method comprises providing a sample from said patient and determining a level of PCT or fragment(s) thereof in said sample, wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. Furthermore, a kit for carrying out the method of the present invention.

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

Abstract: The operating unit comprises an operating element which is adapted to be mechanically excited by means of a piezo driver. The piezo driver comprises a piezo actuator made from a piezoelectric material. The longitudinal extension ends of the piezo actuator have mechanically coupled thereto a conversion gear for converting a length change of the piezo actuator occurring in the effective direction of the piezo actuator into a movement of an element, which is coupled to the conversion gear and to be moved, at an angle not equal to 0 degree relative to the longitudinal extension of the piezo actuator. The conversion gear comprises a first bracket which is of an elastic configuration and/or comprises an elastic material and which, in the area of the longitudinal extension ends of the piezo actuator, is mechanically coupled to the latter.

Abstract: The invention relates to a device for controlling armature solenoid provided with a DC voltage source (14), at least one buffer capacitor (18), which is connected in parallel to the DC voltage source (14) and has a known capacitance (C), and a first switch (28), which is arranged between the DC voltage source (14) and the buffer capacitor (18). The exciter coil (16) and a second switch (30) arranged in series therewith are connected in parallel to the buffer capacitor (18). A control and evaluation unit (22), when the buffer capacitor (18) is charged, opens the first switch (28) and closes the second switch (30) in order to determine, on the basis of the measurement voltage (20), the frequency of the resonant circuit having the capacitance (C) of the buffer capacitor (18) and the inductance (L) of the armature solenoid (12).

Abstract: Polyisocyanate composition containing (A) at least one polyisocyanate obtainable by reacting at least one monomeric isocyanate, (B) at least one solvent containing a mixture of C7-C14 aromatic hydrocarbons, (C) optionally at least one further solvent, (D) optionally at least one Lewis-acidic organic metal compound capable of accelerating the reaction of isocyanate groups with isocyanate-reactive groups, (E) optionally other coatings additives, wherein the amount of cumene in component (B) is less than 1 wt %, preferably less than 0.7 wt %.

Abstract: The operating unit for a vehicle is provided with a housing and an operating element elastically mounted in and/or on the housing, wherein the elastically mounted operating element forms a spring-mass system having a construction-related resonance frequency. The operating unit is further provided with an actuator for pulse-shaped mechanical excitation of the operating element, and a control unit for controlling the actuator when manually actuating the operating element. The resonance frequency is, due to construction, above the highest cut-off frequency that can typically still be detected by receptors for haptic feedback and/or for tactile sensation of a person. The frequency spectrum of the mechanical pulse at the resonance frequency and/or at one of the harmonics of the resonance frequency has no frequency components in that the power density spectrum above the cut-off frequency is energy-free or substantially energy-free.

Abstract: The operating unit for a vehicle comprises a housing with an operating element on the front side, wherein the operating element has a display with a display surface and a cover plate, which defines an operating surface of the operating element, and has at least one projection region projecting laterally over the display, and is elastically laterally moveably mounted on and/or in the housing. An actuator is arranged below the cover plate, said actuator having a drive and a control element driven by the drive. The operating unit is also provided with an elastic actuation arm which protrudes from the cover plate and which is mechanically acted upon by the control element of the actuator at a force application point of the actuation arm.

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

Abstract: The operating unit for a vehicle is provided with a housing and an operating element elastically mounted in and/or on the housing, wherein the elastically mounted operating element forms a spring-mass system having a construction-related resonance frequency. The operating unit is further provided with an actuator for pulse-shaped mechanical excitation of the operating element, and a control unit for controlling the actuator when manually actuating the operating element. The resonance frequency is, due to construction, above the highest cut-off frequency that can typically still be detected by receptors for haptic feedback and/or for tactile sensation of a person. The frequency spectrum of the mechanical pulse at the resonance frequency and/or at one of the harmonics of the resonance frequency has no frequency components in that the power density spectrum above the cut-off frequency is energy-free or substantially energy-free.

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

Abstract: The operating unit for a vehicle comprises a housing with an operating element on the front side, wherein the operating element has a display with a display surface and a cover plate, which defines an operating surface of the operating element, and has at least one projection region projecting laterally over the display, and is elastically laterally moveably mounted on and/or in the housing. An actuator is arranged below the cover plate, said actuator having a drive and a control element driven by the drive. The operating unit is also provided with an elastic actuation arm which protrudes from the cover plate and which is mechanically acted upon by the control element of the actuator at a force application point of the actuation arm.

Abstract: The invention relates to a device for controlling armature solenoid provided with a DC voltage source (14), at least one buffer capacitor (18), which is connected in parallel to the DC voltage source (14) and has a known capacitance (C), and a first switch (28), which is arranged between the DC voltage source (14) and the buffer capacitor (18). The exciter coil (16) and a second switch (30) arranged in series therewith are connected in parallel to the buffer capacitor (18). A control and evaluation unit (22), when the buffer capacitor (18) is charged, opens the first switch (28) and closes the second switch (30) in order to determine, on the basis of the measurement voltage (20), the frequency of the resonant circuit having the capacitance (C) of the buffer capacitor (18) and the inductance (L) of the armature solenoid (12).

Abstract: The operating unit comprises an operating element which is adapted to be mechanically excited by means of a piezo driver. The piezo driver comprises a piezo actuator made from a piezoelectric material. The longitudinal extension ends of the piezo actuator have mechanically coupled thereto a conversion gear for converting a length change of the piezo actuator occurring in the effective direction of the piezo actuator into a movement of an element, which is coupled to the conversion gear and to be moved, at an angle not equal to 0 degree relative to the longitudinal extension of the piezo actuator. The conversion gear comprises a first bracket which is of an elastic configuration and/or comprises an elastic material and which, in the area of the longitudinal extension ends of the piezo actuator, is mechanically coupled to the latter.

Abstract: The piezo drive is provided with a piezo actuator which can be reversibly expanded with respect to its longitudinal extent and has two ends which are averted from one another and also has two lateral sides which are averted from one another. A conversion transmission is coupled to the piezo actuator for converting an expansion and a subsequent contraction of the piezo actuator into in each case a movement which is directed at an angle which is not equal to 0 degrees, in particular of 90° in relation to the longitudinal extent of the piezo actuator. The conversion transmission has an elastic clip which has two receiving legs, which are situated opposite one another and are at a distance from another, and a connecting which extends between said receiving legs and has at least one section which is directed away from the piezo actuator with respect to the position of said piezo actuator or a section which is bent in the direction of said piezo actuator.

Abstract: The operating unit comprises an actuator, which mechanically excites an operating element. The actuator comprises a support strip made of a resilient material. Piezo elements, which are connected to the support strip in a shear-resistant manner, are located on both outer surfaces of the support strip. As a result of the alternate arrangement of the piezo elements, the support strip assumes an undulating form when moving out of its inactivated state. One side of the support strip is mechanically connected to the operating element and the other side is mechanically connected to a counterbalance. The support strip itself is mechanically fixed in the housing. In its inactivated state, the operating element and the counterbalance are at a different distance from one another than in the undulating activated state, wherein they move in opposite directions and thus lead to a compensation of dynamic forces acting on the housing.

Abstract: The operating unit (10) for a vehicle component is provided with a housing (14) having a frame (16) and a display (62) having a transparent cover pane (18) with an edge (22). A plurality of actuators (24) for introducing flexural waves into the cover pane (18) is arranged along the edge (22) of the cover pane (18). A contact surface (34) is assigned to each actuator (24) on the cover pane (18), by means of which contact surface the actuator (24) acts on the cover pane (18) in order to introduce flexural waves into the cover pane (18). The flexural waves introduced into the cover pane (18) by the actuators (24) are superposed in the cover pane (18) and give the cover pane (18) a tactilely sensible, locally resolved surface structure.

Abstract: A method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response and suspected of having an infection. Also, a method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response, wherein the comorbidity is preferably selected from the group comprising metabolic disorder (obesity), diabetes, hypertension, renal disease, thrombosis, malignancy or cancer, and suspected of having an infection. In particular, the method comprises providing a sample from said patient and determining a level of PCT or fragment(s) thereof in said sample, wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. Furthermore, a kit for carrying out the method of the present invention.

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.